End of treatment FDG‐PET in primary mediastinal B‐cell lymphoma treated with R‐chemotherapy: Prognostic indicator and implications for consolidation radiotherapy

摘要

Abstract The ideal therapeutic regimen in primary mediastinal B‐cell lymphoma (PMBCL) is controversial and may include consolidation radiotherapy (RT). An adequate strategy is essential in a population where long‐term effects of RT are significant. We evaluated the prognostic value of end‐of‐treatment (EOT) FDG‐PET in 50 patients receiving rituximab and anthracycline‐containing chemotherapy and its implications for consolidative RT. Thirty patients (60) obtained complete metabolic response (CMR), five received consolidation RT. The remaining patients had partial response (14) and progression (6). Of these, 12 received mediastinal RT, six salvage chemotherapy, and two no further treatment. Five‐year progression free survival was 100 and 48 (95 CI 30‐77) in patients with negative and positive EOT FDG‐PET, respectively (P?